Skip to main content
Back
Watch Compare

CITIUS ONCOLOGY, INC.

Data quality: 83%
CTOR
NASDAQ Manufacturing Chemicals
$0.68
▲ $0.02 (2.27%)
Mkt Cap: 59.59 M
Price
$0.68
Mkt Cap
59.59 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -12.85 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-52.06%
Above sector avg (-53.58%)
ROIC-43.72%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio0.83
Interest Coverage-109.05

Valuation

PE (TTM|NTM|2027)
-2.52 | 1.73 | 1.74
Below sector avg (-1.48)
P/B Ratio1.02
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1366 peers)
Metric Stock Sector Median
P/E -2.5 -1.5
P/B 1.0 1.6
ROE % -52.1 -53.6
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

1 analyst
Strong Buy
Current
$0.68
+788.9%
Target
$6.00
$6.00
$6.00
$6.00
Forecast
Forward P/E 1.73
Forward EPS $0.39
Est. Revenue 118.95 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $0.39
$0.39 – $0.39
 118.95 M 1
FY2026 -$0.19
-$0.19 – -$0.19
 38.87 M 1

Earnings Surprises

Last 5 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.04 -$0.06 -50.0%
Q32025 -$0.06 -$0.06 0.0%
2026-Q1 -$0.01 -$0.06 -500.0%
Q22025 -$0.15 -$0.08 +46.7%
Q12025 -$0.09 -$0.11 -22.2%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -23.64 M
ROE -52.06% ROA -23.44%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12.85 M
ROIC -43.72% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.83
Interest Coverage -109.05 Asset Turnover N/A
Working Capital -7.56 M Tangible Book Value 58.41 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.52 Forward P/E 1.73
P/B Ratio 1.02 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0.50 Fwd Earnings Yield 57.80%
FCF Yield -21.56%
Market Cap 59.59 M Enterprise Value 52.29 M
Per Share
EPS (Diluted TTM) -0.31 Revenue / Share N/A
FCF / Share -0.15 OCF / Share -0.15
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 54.35%
SBC-Adj. FCF -22.83 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue — — — —
Net Income -24.76 M -21.15 M 2.42 M 380,811.0
EPS (Diluted) -0.34 -0.31 0.27 0.12
Gross Profit — — — —
Operating Income -23.52 M — -1.01 M -138,115.0
EBITDA — — — —
R&D Expenses 6.42 M 4.93 M — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense 218,032.0 — — —
Income Tax 1.06 M 576,000.0 — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 100.94 M 84.37 M 72.62 M 68.19 M
Total Liabilities 56.08 M 38.23 M — —
Shareholders' Equity 44.87 M 46.14 M -1.99 M 345,508.0
Total Debt — — — —
Cash & Equivalents — — — —
Current Assets 27.54 M 10.97 M 58,200.0 377,344.0
Current Liabilities 49.49 M 32.70 M 2.05 M 31,836.0